Lin BioScience, Inc. (TPEX:6696)
Taiwan · Delayed Price · Currency is TWD 392.50
-3.50 (-0.88%)
At close: Mar 13, 2026
Lin BioScience Market Cap
Lin BioScience has a market cap or net worth of 32.47 billion as of March 13, 2026. Its market cap has increased by 187.76% in one year.
Market Cap
32.47B
Enterprise Value
29.78B
Revenue
n/a
Ranking
n/a
PE Ratio
n/a
Stock Price
392.50
Market Cap Chart
Since October 8, 2018, Lin BioScience's market cap has increased from 2.92B to 32.47B, an increase of 1,013.46%. That is a compound annual growth rate of 38.30%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Mar 13, 2026 | 32.47B | -1.13% |
| Dec 31, 2025 | 32.84B | 203.76% |
| Dec 31, 2024 | 10.81B | 20.85% |
| Dec 29, 2023 | 8.95B | -28.90% |
| Dec 30, 2022 | 12.58B | -1.94% |
| Dec 30, 2021 | 12.83B | 83.66% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 28, 2018 | Upgrade Pro | Upgrade Pro |
| Oct 8, 2018 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Pell Bio-Med Technology | 37.07B |
| Lumosa Therapeutics | 25.46B |
| Oneness Biotech | 24.93B |
| Sunmax Biotechnology | 21.16B |
| Polaris Group | 20.61B |
| EirGenix | 17.46B |
| AP Biosciences | 14.29B |
| TaiMed Biologics | 13.96B |